TScan Therapeutics, Inc. (TCRX) Fair Value 2026

TCRX · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.6 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-07-13, TScan Therapeutics, Inc. (TCRX) trades at $1.03, approximately 4% below CirclFi’s Bayesian DCF fair value of $1.08. QOC: 6.6/10. Value Trap Risk: 24/100 (SAFE). 9/13 models active.

Key Facts

Ticker
TCRX
Price
$1.03
Quality Score
6.6/10
Value Trap Risk
24/100
Models Active
9/13
Last Updated
Strength: ML-RIV suggests +81.7% upside with 46% confidence
Risk: Limited model coverage (9/13) may reduce confidence

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($1.03)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $1.08 +4.4%
CUCE Ensemble
Low Conviction
 $1.62 +57.6%
First Chicago
Medium Conviction
 $0.35 -65.7%
ML-RIV
Medium Conviction
 $1.87 +81.7%

Unlock the Full Matrix

Access 5 additional models including Dynamic NAV, PWERM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is TScan Therapeutics, Inc. (TCRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for TScan Therapeutics, Inc.. Trading at $1.03 against an estimated intrinsic value of $1.54, 7 of 9 active models flag meaningful upside of +49.0% on average. The most optimistic model, Dynamic NAV, places fair value at $3.25 (+215.1%), while First Chicago — the most conservative — estimates $0.35 (-65.7%). This +280.8% gap reflects genuine analytical uncertainty about TScan Therapeutics, Inc.'s intrinsic worth.

What Do the Models Say About TCRX?

9 of 13 models are currently active for TCRX. Of these, 8 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates TCRX's intrinsic value at $1.08, implying +4.4% upside from the current price. See which stocks rank higher →

How Does TCRX Rank in Biological Products, (No Diagnostic Substances)?

Among 139 Biological Products, (No Diagnostic Substances) stocks, TCRX ranks #24 by Quality of Company score. CirclFi's QOC score of 6.6/10 evaluates 32 fundamental signals. A score of 6.6 indicates above-average quality.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

TScan Therapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is TCRX a Value Trap?

CirclFi's Value Trap algorithm assigns TCRX a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for TScan Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, TScan Therapeutics, Inc. is rated at 6.6/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +280.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TCRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TCRX's 9 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy TScan Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About TScan Therapeutics, Inc.

What is TScan Therapeutics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, TScan Therapeutics, Inc. (TCRX) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.08. The Quality of Company score is 6.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TCRX overvalued or undervalued right now?

At $1.03, 8 of 9 active models suggest TCRX may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits TScan Therapeutics, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 6.6 mean for TCRX?

TScan Therapeutics, Inc.'s QOC of 6.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on TCRX?

CirclFi analyzes TCRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is TCRX a value trap in 2026?

TScan Therapeutics, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on TCRX.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access